← Evidence map

ArticleSurgery today2026

A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarcinoma (BR + UR-LA) (CSGO-HBP-008).

Yoshiteru Katsura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarcinoma (BR + UR-LA) (CSGO-HBP-008). | OpenQuestion